Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer.
Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer.
复制标题
DOI：
10.1038/bjc.1998.524
复制
发表时间：
1998-08
影响因子：
8.8
通讯作者：
Schmiegel, W
中科院分区：
文献类型：
--
作者：
Petrasch, S;Welt, A;Reinacher, A;Graeven, U;Konig, M;Schmiegel, W
紫杉醇单药治疗对食管鳞状细胞癌和腺癌均有效。然而，只有有限的数据是关于紫杉醇与其他细胞毒性药物在这个实体的组合。在一个多中心的研究中，对不能切除的III期复发或转移性肿瘤患者，紫杉醇90 mg m（-2）静脉给药3 h，随后顺铂50 mg m（-2）静脉给药。这些课程每14天重复一次。20例食管鳞状细胞癌或腺癌患者可评价缓解。总缓解率为40%（8/20），其中临床完全缓解率为15%（3/20）。70%的患者实现了临床获益反应，定义为吞咽困难缓解和/或体重显著增加。仅10%的患者发生CTC 3级中性粒细胞减少;未发生4级中性粒细胞减少和重度血小板减少。在5%的患者中观察到CTC 4级神经毒性。顺铂/紫杉醇每14天给药一次，对预后不良的食管癌患者有效，毒性可接受。
Single-agent therapy with paclitaxel is effective against both squamous cell carcinoma and adenocarcinoma of the oesophagus. However, only limited data are available on the combination of paclitaxel with other cytotoxic drugs in this entity. Patients with unresectable stage III, recurrent or metastatic tumours were treated in a multicentre setting with paclitaxel 90 mg m(-2) given over 3 h intravenously, followed by cisplatin 50 mg m(-2). The courses were repeated every 14 days. Twenty patients with squamous cell carcinoma or adenocarcinoma of the oesophagus were evaluable for response. The overall remission rate was 40% (8/20), including 15% (3/20) clinically complete responses. Clinical benefit response, defined as relief of dysphagia and/or significant gain in weight, was achieved in 70% of the patients. Neutropenia of CTC grade 3 occurred only in 10% of the patients; no grade 4 neutropenia and no severe thrombocytopenia was encountered. CTC grade 4 neurotoxicity was seen in 5% of patients. Cisplatin/paclitaxel administered every 14 days, was effective in patients with poor prognosis oesophageal cancer and toxicity was acceptable.